Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

FHIR-Enhanced RealRisks to Improve Accuracy of Breast Cancer Risk Assessment and Decision Support in High-Risk Women

Trial Status: active

This clinical trial tests the impact of Fast Healthcare Interoperability Resources (FHIR)-enhanced RealRisks on the accuracy of breast cancer risk assessment and decision support in women at high-risk for breast cancer. Women identified as high-risk for breast cancer may benefit from personalized risk-reducing strategies. However, barriers exist for women to obtain these risk-reducing strategies including the time required to conduct risk assessment for each woman. Electronic health records (EHRs), a common source for populating risk assessment models present challenges, including missing data, as well as data type. Data may be more accurate when provided by patients compared to EHRs. RealRisks, a decision aid, assists in women's understanding of breast cancer risk and uses patient-entered data to calculate risk. FHIR-enhanced RealRisks uses both patient-generated health data and EHR data to populate information for breast cancer risk, maximizing the strengths of both types of data. FHIR-enhanced RealRisks may improve the accuracy of breast cancer risk assessment and decision support in women at high-risk for breast cancer.